CN104693281A - Angiostatin activating agent polypeptide and application thereof - Google Patents
Angiostatin activating agent polypeptide and application thereof Download PDFInfo
- Publication number
- CN104693281A CN104693281A CN201510157244.5A CN201510157244A CN104693281A CN 104693281 A CN104693281 A CN 104693281A CN 201510157244 A CN201510157244 A CN 201510157244A CN 104693281 A CN104693281 A CN 104693281A
- Authority
- CN
- China
- Prior art keywords
- angiostatin
- polypeptide
- application
- activator polypeptide
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the field of drugs, in particular to polypeptide for activating angiostatin and treating malignant tumors. The sequence of the polypeptide is EALALMYYHSQSLRKTYP and is a brand new sequence. By means of the polypeptide, the angiostatin can be activated out of a body, proliferation of vascular endothelial cells can be suppressed, the tumor-bearing mice survival rate can be increased in an in-vivo test, and the potential new drug development value is achieved.
Description
Technical field
The present invention relates to angiostatin activator polypeptide and application thereof, be specifically related to that there is activating vessels chalone, the polypeptide for the treatment of malignant tumour.
Background technology
Folkman in 1971 proposes growth and metastasis of tumours and relies on new vessel generation.And after thinking that solid tumor is formed, its development can be divided into without blood vessel phase and two stages of blood vessel phase.Without the blood vessel phase, the existence of minimal neoplastic relies on interstitial disperse blood supply around, and linearly, tumour is limited within 1mm ~ 2mm the speed of growth, and oncocyte number is less than 10
5~ 10
6individual, force tumour to be in " dormant state "; Intravasation after date, tumor tissues is the blood supply of perfusion property, and the exponentially property growth of knurl body, can increase 1. 6 ten thousand times after 2 weeks.New vessel not only provides nutrition required for tumour and oxygen, gets rid of meta-bolites, and is the approach of distant metastasis.Therefore, block tumor angiogenesis and just may stop growth and metastasis of tumours, anti-new vessel therapy also one of means becoming oncotherapy.
Angiostatin is the hydrolysate of proplasmin, has stronger angiogenesis inhibiting activity.Large quantity research confirms that angiostatin can suppress growth and the migration of endotheliocyte in vitro, new vessel can be suppressed to be formed in vivo in test, thus inducing apoptosis of tumour cell, Tumor suppression grows, and tumour is in " dormant state ".
Therefore, activating vessels chalone, can effectively suppress vascular endothelial cell proliferation in body, the growth of Tumor suppression.Thus, reach the effect for the treatment of tumour.
At present, do not have the angiostatin activator polypeptide of ripe exploitation to come out, be used for the treatment of malignant tumour.
Angiostatin activator polypeptide in this patent proved before the treatment in row gland cancer effectively, there is the prospect developed in other tumor models.
Summary of the invention
goal of the invention
The invention provides brand-new sequence, this sequence is angiostatin activator polypeptide, has good curative effect to malignant tumour.
technical scheme
angiostatin activator polypeptide, is characterized in that its sequence is EALALMYYHSQSLRKTYP.
Angiostatin activator polypeptide treatment malignant tumour, as the application in prostate cancer medicine.
beneficial effect
Utilize solid-phase synthesis chemosynthesis angiostatin activator polypeptide, this polypeptide has brand-new sequence, and this polypeptide can be hydrolyzed by external promotion proplasmin, and treatment malignant tumour, as prostate cancer.The angiostatin activator polypeptide that we find can suppress vascular endothelial cell proliferation vigor simultaneously, and improves tumor-bearing mice survival rate in testing in vivo, has potential new drug development value.
Embodiment
Embodiment 1
Angiostatin activator polypeptide is to the activity of extracorporeal hydrolysis proplasmin.
Adopt the former hydrolysate of ELISA method detection fibers plasmin---angiostatin.Be substrate by the Tryptase of the 1mg/ml of 1ml, in substrate solution, add 2 respectively, 4, the angiostatin activator polypeptide (the raw work synthesis in Shanghai) of 8ng and positive control drug metalloprotease 10ng, at 37 DEG C, after reaction 5min, centrifugal, get supernatant, with the content of solution Effect of Angiostatin after ELISA method reaction, result shows, 2,4, the angiostatin that produces of the angiostatin activator polypeptide of 8ng and metalloprotease is respectively 24.87,31.98,53.98 μMs.
Embodiment 2
Angiostatin activator polypeptide is to the growth of vitro culture human vascular endothelial and survival IC50.
Adopt MTT colorimetry.By the human vascular endothelial HUVEC of logarithmic growth, with 1.0 × 10
5add in 96 well culture plates, cultivate 24h, experimental port, positive drug control hole add Experimental agents angiostatin activator polypeptide (the raw work synthesis in Shanghai) and the positive control medicine taxol of different concns respectively; Blank group adds the solvent of same volume.Five multiple holes are established in every hole, cultivate 48h, respectively 0h, 2h, 8h, 14h, 20h, 24h, 36h, the every hole of 48h adds MTT, after effect 4h, add DMSO, hatch 30min, absorbance A value is measured, by formula HUVEC growth inhibition ratio=(1-experimental group light absorption value/control group light absorption value) × 100% at microplate reader 620nm place.The IC50 calculating Experimental agents is 19.32 μMs.
Embodiment 3
With vigor in the body of tumor model detection angiostatin activator polypeptide.
Set up tumor model of prostate cancer, positive control medicine taxol; Blank group adds the solvent of same volume, and experimental group polypeptide (the raw work synthesis in Shanghai) establishes 3 dosage: 2,4,8 mg/Kg.After 21 days, observe mouse survival quantity, calculate survival rate.Result shows, and angiostatin activator polypeptide can protect small white mouse effectively, and improve the survival rate of tumor-bearing mice, survival rate reaches 81.54%.
SEQUENCE LISTING
Pu Luoda bio tech ltd, <110> Suzhou
<120> angiostatin activator polypeptide and application thereof
<130>
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 18
<212> PRT
<213> artificial sequence
<400> 1
Glu Ala Leu Ala Leu Met Tyr Tyr His Ser Gln Ser Leu Arg Lys Thr
1 5 10 15
Tyr Pro
Claims (3)
1. angiostatin activator polypeptide, is characterized in that its sequence is EALALMYYHSQSLRKTYP.
2. the application of angiostatin activator polypeptide in tumor as claimed in claim 1.
3. the application of angiostatin activator polypeptide as claimed in claim 1 before the treatment in row gland cancer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510157244.5A CN104693281A (en) | 2015-04-06 | 2015-04-06 | Angiostatin activating agent polypeptide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510157244.5A CN104693281A (en) | 2015-04-06 | 2015-04-06 | Angiostatin activating agent polypeptide and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104693281A true CN104693281A (en) | 2015-06-10 |
Family
ID=53340868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510157244.5A Withdrawn CN104693281A (en) | 2015-04-06 | 2015-04-06 | Angiostatin activating agent polypeptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104693281A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105039293A (en) * | 2015-08-20 | 2015-11-11 | 倪勤华 | Angiostatin activator polypeptide |
| CN106496308A (en) * | 2016-10-08 | 2017-03-15 | 苏州普罗达生物科技有限公司 | A kind of φt cell receptor activator polypeptide and its application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680430A (en) * | 2005-01-12 | 2005-10-12 | 复旦大学 | Mimic peptide of human plasminogen activator and preparation thereof |
| CN101219219A (en) * | 2007-01-10 | 2008-07-16 | 北京普罗吉生物科技发展有限公司 | Complex containing vascellum chalone or its fragment, preparation method and application thereof |
-
2015
- 2015-04-06 CN CN201510157244.5A patent/CN104693281A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1680430A (en) * | 2005-01-12 | 2005-10-12 | 复旦大学 | Mimic peptide of human plasminogen activator and preparation thereof |
| CN101219219A (en) * | 2007-01-10 | 2008-07-16 | 北京普罗吉生物科技发展有限公司 | Complex containing vascellum chalone or its fragment, preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| S. GATELY等: "The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES》 * |
| 张扬等: "血管抑素在前列腺癌中的表达及与VEGF相关性的实验研究", 《沈阳医学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105039293A (en) * | 2015-08-20 | 2015-11-11 | 倪勤华 | Angiostatin activator polypeptide |
| CN106496308A (en) * | 2016-10-08 | 2017-03-15 | 苏州普罗达生物科技有限公司 | A kind of φt cell receptor activator polypeptide and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | Anti-tumor and anti-metastatic roles of cordycepin, one bioactive compound of Cordyceps militaris | |
| Zhang et al. | Antiviral activity of a synthesized shikonin ester against influenza A (H1N1) virus and insights into its mechanism | |
| CN104693281A (en) | Angiostatin activating agent polypeptide and application thereof | |
| 김정목 et al. | AMPK activators: mechanisms of action and physiological activities | |
| CN104693282A (en) | Angiostatin activator polypeptide and application thereof | |
| CN104693283A (en) | Angiostatin activating agent polypeptide and application thereof | |
| CN105039293A (en) | Angiostatin activator polypeptide | |
| CN105039294A (en) | Hydrolyzed plasminogen polypeptides | |
| CN104694521A (en) | Hydrolysis plasminogen polypeptide and application thereof | |
| CN104694520A (en) | Hydrolyzed profibrinolysin polypeptide and application thereof | |
| CN105982895A (en) | TOPK inhibitor as antitumor drug | |
| CN105769863A (en) | Application of Tipranavir in anti-cancer drug and anti-cancer drug | |
| CN103130871B (en) | Preparation method and application of prodrug of endopeptidase activated doxorubicin | |
| CN104726438A (en) | Hydrolysis plasminogen polypeptide and application thereof | |
| CN104693289A (en) | Tight-junction protein inhibitor polypeptide and application thereof | |
| CN104725481A (en) | Vascular endothelial calnexin antagonist polypeptide and application thereof | |
| CN104693280A (en) | Signal-transducer-and-activator-of-transcription suppressing polypeptide and application thereof | |
| CN104744571A (en) | VE-cadherin (Vascular Endothelium-Cadherin) antagonist polypeptide and application thereof | |
| CN104045689B (en) | A kind of about somatostatin receptor agonist polypeptide and application thereof | |
| CN104045691B (en) | Npas2 protein agonist polypeptide and application thereof | |
| CN104887690B (en) | Application of the chonglou saponin in antitumor drug is prepared | |
| CN106749547A (en) | A kind of eukaryotic initiation factor 2B inhibitor polypeptide and its application | |
| CN103739672B (en) | Polyethylene glycol modified polypeptide inhibiting VEGFR2 (vascular endothelial growth factor receptor2) tyrosine kinase and application thereof | |
| CN109422652A (en) | Application of the salicylic derivative of chloroethene acyloxy in drug | |
| CN104725488A (en) | Tight junction protein inhibitor polypeptide and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150610 |
|
| WW01 | Invention patent application withdrawn after publication |